12.49 USD
+0.01 (+0.08%)
Overall CDMO gets a fundamental rating of 2 out of 10. We evaluated CDMO against 528 industry peers in the Biotechnology industry. CDMO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CDMO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year CDMO has reported negative net income.
- In the past year CDMO had a positive cash flow from operations.
- In multiple years CDMO reported negative net income over the last 5 years.
- Of the past 5 years CDMO 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -47.00%, CDMO is in line with its industry, outperforming 48.85% of the companies in the same industry.
- CDMO's Return On Equity of -339.34% is on the low side compared to the rest of the industry. CDMO is outperformed by 76.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | -339.34% | ||
| ROIC | N/A |
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CDMO has a Gross Margin of 7.68%. This is in the better half of the industry: CDMO outperforms 73.81% of its industry peers.
- In the last couple of years the Gross Margin of CDMO has declined.
- The Profit Margin and Operating Margin are not available for CDMO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
2. Health
2.1 Basic Checks
- CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CDMO has more shares outstanding
- The number of shares outstanding for CDMO has been increased compared to 5 years ago.
- CDMO has a worse debt/assets ratio than last year.
2.2 Solvency
- CDMO has an Altman-Z score of -0.51. This is a bad value and indicates that CDMO is not financially healthy and even has some risk of bankruptcy.
- CDMO's Altman-Z score of -0.51 is fine compared to the rest of the industry. CDMO outperforms 61.95% of its industry peers.
- CDMO has a Debt/Equity ratio of 3.58. This is a high value indicating a heavy dependency on external financing.
- CDMO's Debt to Equity ratio of 3.58 is on the low side compared to the rest of the industry. CDMO is outperformed by 84.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.51 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
- CDMO has a Current Ratio of 1.30. This is a normal value and indicates that CDMO is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.30, CDMO is doing worse than 83.89% of the companies in the same industry.
- CDMO has a Quick Ratio of 1.30. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.92, CDMO is doing worse than 87.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
- The earnings per share for CDMO have decreased strongly by -1305.88% in the last year.
- CDMO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.80%.
- CDMO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.15% yearly.
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
3.2 Future
- The Earnings Per Share is expected to grow by 27.71% on average over the next years. This is a very strong growth
- CDMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.14% yearly.
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- CDMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CDMO's earnings are expected to grow with 27.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y27.71%
5. Dividend
5.1 Amount
- No dividends for CDMO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CDMO (2/4/2025, 8:00:02 PM)
12.49
+0.01 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10 2024-12-10/amc
Earnings (Next)04-22 2025-04-22/amc
Inst Owners105.25%
Inst Owner Change0%
Ins Owners0.95%
Ins Owner Change0%
Market Cap801.11M
Revenue(TTM)150.44M
Net Income(TTM)-152.05M
Analysts74.55
Price Target12.75 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-92.85%
Min EPS beat(2)-125.28%
Max EPS beat(2)-60.43%
EPS beat(4)0
Avg EPS beat(4)-1306.42%
Min EPS beat(4)-4971.9%
Max EPS beat(4)-60.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.13%
Min Revenue beat(2)-3.38%
Max Revenue beat(2)-2.89%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-3.38%
Max Revenue beat(4)-0.02%
Revenue beat(8)3
Avg Revenue beat(8)-3.35%
Revenue beat(12)7
Avg Revenue beat(12)0.75%
Revenue beat(16)11
Avg Revenue beat(16)3.84%
PT rev (1m)0%
PT rev (3m)-7.41%
EPS NQ rev (1m)-9.09%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-1.69%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.32 | ||
| P/FCF | N/A | ||
| P/OCF | 152.36 | ||
| P/B | 17.88 | ||
| P/tB | 17.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.08
OCFY0.66%
SpS2.35
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47% | ||
| ROE | -339.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 7.68% | ||
| FCFM | N/A |
ROA(3y)-3.99%
ROA(5y)-4.97%
ROE(3y)-52.56%
ROE(5y)-37.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-44.47%
GM growth 5Y-17.19%
F-Score4
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 119.78% | ||
| Cap/Sales | 9.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -0.51 |
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)874.1%
Cap/Depr(5y)606.28%
Cap/Sales(3y)40.63%
Cap/Sales(5y)27.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1305.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y86.15%
EPS Next 2Y38.79%
EPS Next 3Y27.71%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.8%
Revenue growth 3Y13.42%
Revenue growth 5Y21.15%
Sales Q2Q%31.84%
Revenue Next Year17.28%
Revenue Next 2Y17.02%
Revenue Next 3Y18.3%
Revenue Next 5Y22.14%
EBIT growth 1Y-69.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y71.06%
EBIT Next 5YN/A
FCF growth 1Y89.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y277.64%
OCF growth 3Y-29.44%
OCF growth 5YN/A
AVID BIOSERVICES INC / CDMO FAQ
What is the ChartMill fundamental rating of AVID BIOSERVICES INC (CDMO) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CDMO.
What is the valuation status of AVID BIOSERVICES INC (CDMO) stock?
ChartMill assigns a valuation rating of 1 / 10 to AVID BIOSERVICES INC (CDMO). This can be considered as Overvalued.
Can you provide the profitability details for AVID BIOSERVICES INC?
AVID BIOSERVICES INC (CDMO) has a profitability rating of 2 / 10.
What is the earnings growth outlook for AVID BIOSERVICES INC?
The Earnings per Share (EPS) of AVID BIOSERVICES INC (CDMO) is expected to grow by 86.15% in the next year.
Is the dividend of AVID BIOSERVICES INC sustainable?
The dividend rating of AVID BIOSERVICES INC (CDMO) is 0 / 10 and the dividend payout ratio is 0%.